



## Curriculum Vitae

Personal information **Maia Uusküla**

### Work experience

---

1. Employer: State Agency of Medicines
  - Start date: 081994
  - End date:
  - Position: Head of the Department of Post\_Authorisation Safety
  - Activities: Overall responsibility for post\_marketing safety control of human medicines, national and EU procedures Work\_flow management in the Dep. of Post\_Authorisations Safety (Bureau of Pharmacovigilance and Bureau of Statistics) Maintenance of the national pharmacovigilance system for human medicinal products, promotion of the system to the physicians, evaluation of suspected adverse drug reaction reports, signal detection Assessment of PSURs (EU WS procedure, RMP/DC renewals) Assessment of PSMFs Assessment of RMP's and risk minimisation materials Assessment of safety variations for nationally authorised products. Monitoring of compliance with pharmacovigilance regulatory obligations of Estonian MAH's National and EU marketing authorisation procedures for human medicinal products, EU requirements for safety evaluation of human medicines. National and EU requirements for product labelling. EU system and requirements of pharmacovigilance of the human medicinal products. EU requirements of pharmacovigilance inspections, PSMF, RMP's, PSURs
  - Country: Estonia

### Education and training

---

1. Subject: University of Tartu, Medical Faculty
  - Start date: 1988
  - End date: 2004
  - Qualification: Doctor of Human Medicine
  - Organisation:
  - Country: Estonia

### Additional information

---

#### Publications

Ivask M, Kurvits K, Uusküla M, Juppõ A, Laius O, Siven M. Compliance with Pregnancy Prevention Recommendations for Isotretinoin Following the Amendment of the European Union Pregnancy Prevention Program: A Repeat Study in Estonia. *Drugs Real World Outcomes*. 2023;10.1007/s40801-023-00381-3. <https://doi.org/10.1007/s40801-023-00381-3>

Kurvits K, Uusküla M, Vestman H, Laius O. Outpatient fluoroquinolone use in relation to European Medicines Agency's recommendation: An Estonian nationwide drug utilization study. *Pharmacoepidemiol Drug Saf*. 2023; 1- 8. doi:10.1002/pds.5593

<https://onlinelibrary.wiley.com/share/author/TDZPRRUWJRYTN4BKWTPR?target=10.1002/pds.5593>

Kurvits K, Blõndal M, Lass J, Uusküla M. Trimetasidiin kui reservreea preparaata tänapäevases südame isheemiatõve ravis. *Perearst* 2022; 11(185):33-35.

<https://med24.ee/ajakirjad/perearst/detsember-2022/trimetasidiin-kui-reservreea-preparaat-t%C3%A4nap%C3%A4evases-s%C3%BCdame>

Kurvits K, Laius O, Uusküla M, Vestman H. Uroinfektsioonide ravi nitrofurantoiiniga 2019. aastal. *Eesti Arst*. 2022;101(6-7):343-347. <https://doi.org/10.15157/ea.vi.19047>

Kurvits K, Laius O, Uusküla M, Laanpere M. Trends in the use of hormonal contraception in Estonia 2005-2019 and the risk of arterial and venous thromboembolism: a population-based study. *Eur J Contracept Reprod Health Care*. 2021 Oct;26(5):413-420. doi:10.1080/13625187.2021.1931839.

<https://www.tandfonline.com/eprint/GY7UUSVBBUTUAXDGMBS/full?target=10.1080/13625187.2021.1931839>

Rakitin A, Kurvits K, Laius O, Uusküla M, Haldre S. Pre-pregnancy counseling for women with epilepsy: Can we do better? *Epilepsy & Behavior*, 2021;125. doi:10.1016/j.yepbeh.2021.108404.

<https://www.sciencedirect.com/science/article/abs/pii/S152550502100665X>

Kurvits K, Sopp E, Keerma K, Laius O, Uusküla M, Volmer D. Maksaensüümide aktiivsuse jälgimine agomelatiini kasutamisel: praktika muutumist võrdlev uuring ja haigusjuhu kirjeldus. Eesti Arst. 2021;100(8):421–6. <https://ojs.utlib.ee/index.php/EA/article/view/18075>

Kurvits K, Uusküla M, Laius O, Jaanson P. Bensodiasepiinide ja Z-ravimite ambulatoorne kasutamine Eestis. Eesti Arst 2020; 99(8):472–479

Uusküla A, Raag M, Kurvits K, Laius O, Uusküla M, Oselin K. Trends in opioid prescribing in Estonia (2011 - 2017). Pharmacol Res Perspect. 2020;e00577.

Kurvits K, Laius O, Uusküla M, Haldre S, Rakitin A. Valproic acid prescription trends among females of childbearing age in Estonia: A 14-year nationwide prescription database study. Seizure Eur J Epilepsy. 2020;76:28–31.

Kurvits K, Rulli R, Uusküla M, Laius O. Digoksiin – kas vanima südameravimi kasutamisel järgitakse ettenähtud soovitusi? Eesti Arst 2020; 99(1):42-47

Kurvits K, Uusküla M, Laius O, Kiisk K. Talidomiid ja selle analoogid – näide tänapäevasest riskijuhtimisest ravimiohutuses. Eesti Arst 2019; 98(3):168–172

Kurvits K, Uusküla M, Laius O. Trimetasidiini kasutamise muutus pärast kasutamispriirangute rakendamist. Eesti Arst 2018; 97(10):572–576

Uusküla, A., Pisarev, H., Kurvits, K. et al. Compliance with Pregnancy Prevention Recommendations for Isotretinoin in Estonia in 2012–2016. Drugs - Real World Outcomes (2018) 5: 129. <https://doi.org/10.1007/s40801-018-0135-z>

Kurvits K, Uusküla M, Laius O. Flupirtini kasutamisele kehtestatud piirangute järgimine. Eesti Arst 2018; 97(4):220–224

Kurvits K, Uusküla M, Laius O. Valproehappe kasutamine fertiilses eas naistel. Eesti Arst 2017; 96(9):544–550

Kurvits K, Sepp J, Uusküla M, Laius O. Co-prescribing of renin-angiotensin system (RAS) acting agents is decreasing in Estonia. European Drug Utilisation Research Group Conference 15-17.11.2017, P12F.2

Kurvits K, Uusküla M, Laius O. Agomelatiinraviga seotud riskivähendamise meetmed praktikas. Eesti Arst 2016; 95(10):687–689

Uusküla M, Kurvits K, Laius O. Ravimitega seotud riskide vähendamise meetmed. Eesti Arst 2016; 95(10):684–686

Irs A, Laius O, Uusküla M. Uued andmed viitavad liigsele agarusele dronedarooni kasutamisel kodade virvendusarütmia ravis (Unnecessary haste in introducing dronedarone into widespread use – new safety information). Eesti Arst 2011; 90(9):422–426

Irs A, Uusküla M. Uued suukaudsed tromboosivastased ravimid dabigatran ja rivaroksabaan (New oral anticoagulants: dabigatran and rivaroxaban). Eesti Arst 2011; 90(5):232–235

Uusküla M, Imelik H, Maimets M, Irs A. Läkakõhavastaste vaktsiinide efektiivsus ja ohutus (Efficacy and safety of pertussis vaccines). Lege Artis 2005;11(46):32-33.

## Projects

SCOPE

WHO AEFI programmes, acting as WHO consultant - sub-regional trainings (2022 Kazaksan, 2023 Bosnia and Herzegovina, 2024 Uzbekistan and Turkmenistan)

## Memberships

## Other Relevant Information